Iter-4360dd15-0049-transcript
第 49 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 PMID 38310895 mmc1 Crossref references 临床候选 19"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0047-transcript", "tags": "iteration transcript", "modified": "20260424193836000", "preview": "!! 第 47 轮执行轨迹
→ call search_memory({\\\"limit\\\":8,\\\"query\\\":\\\"4360dd15 PMID 38310895 mmc1.pdf supplementary tabl"}, {"title": "Iter-4360dd15-0037-transcript", "tags": "iteration transcript", "modified": "20260424191347000", "preview": "!! 第 37 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 PMID 38310895 mmc1 pdf 19 纳入研究\"}) → call list_recent({\"n\":6}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0047-transcript\", \"t → call list_recent({"n":8})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0048-reflection", "modified": "20260424194120000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424194120000", "tags": "pinned focus"}, {"title": "先拿可读副本再抽取", "modified": "20260424194120000", "tags": "lesson evidence-retrieval supplementary-material access-block"}, {"title": "Iter-4360dd15-0048-transcript", "modified": "20260424194115000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0048-crossref-trialish-candidate-extraction", "modified": "20260424194106000", "tags": "4360dd15 knowledge fact experiment evidence-retrieval"}, {"title": "Iter-4360dd15-0047-reflection", "modified": "20260424193842000", "tags": "iteration reflection"}, {"title": "先确认可读副本再抽取", "modified": "20260424193842000", "tags": "lesson evidence-retrieval supplementary-material access-block"}, {"title": "Iter-4360dd15-0047-transcript", "modified": "20260424193836000", "tags": "iteration transcript"}]}
→ call read_note({"title":"Iter-4360dd15-0048-crossref-trialish-candidate-extraction"})
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0048-crossref-trialish-candidate-extraction", "tags": "4360dd15 knowledge fact experiment evidence-retrieval", "text": "!! 本轮结果：用 Crossref references 替代 mmc1.pdf 镜像，抽取到可复现的临床候选集\n\n本轮没有找到可打开的 mmc1.pdf 二次转载，但通过 DOI `10.1016/S2666-7568(23)00258-1` 的 Crossref 机器可读 references，拿到了综述的 75 条参考文献数组，并用本地规则把候选压缩到人类临床文章。\n\n!! 可复现代码\n
\n\n!! 目前得到的 14 条 human trial-ish 候选\n- 25 `10.1016/ → call run_python({"code":"import requests, re, json\n\ndoi='10.1016/S2666-7568(23)00258-1'\nmsg=requests.get(f'https://api.crossref.org/works/{doi}', timeout=30,\n headers={'User-Agent':'Mozilla/5.0'}).json()['message']\nrefs=msg['reference']\nkw = re.compile(r'rapamycin|sirolimus|everolimus|temsirolimus|rapalog|mTOR inhibitor|mammalian target of rapamycin', re.I)\ntrialish_markers = re.compile(r't)
→ call web_search({"limit":6,"query":"\"10.1016/S2666-7568(23)00258-1\" mTOR inhibitors older adults phase 2b phase 3 randomised trials"})
→ call web_search({"limit":6,"query":"\"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis\" trial reference"})
【tool:run_python】
{"ok": true, "stdout": " \"article-title\": \"Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study\",\n \"volume\": \"67\",\n \"author\": \"Bruyn\",\n \"year\": \"2008\",\n \"journal-title\": \"Ann Rheum Dis\"\n }\n },\n {\n \"idx\": 42,\n \"title\": \"Low-dose sirolimus immunoregulation therapy in patients with active rheumatoid arthritis: a 24-week follow-up of the randomized, open-label, parallel-controlled trial\",\n \"year\": \"2019\",\n \"doi\": \"10.1155/2019/7684352\",\n \"raw\": {\n \"key\": \"10.1016/S2666-7568(23)00258-1_bib45\",\n \"doi-asserted-by\": \"crossref\",\n \"DOI\": \"10.1155/2019/7684352\",\n \"article-title\": \"Low-dose sirolimus immunoregulation therapy in patients with active rheumatoid arthritis: a 24-week follow-up of the randomized, open-label, parallel-controlled trial\",\n \"volume\": \"2019\",\n \"author\": \"Wen\",\n \"year\": \"2019\",\n \"journal-title\": \"J Immunol Res\"\n }\n },\n {\n \"idx\": 67,\n \"title\": \"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study\",\n \"year\": \"2016\",\n \"doi\": \"10.1016/S0140-6736(16)31419-2\",\n \"raw\": {\n \"key\": \"10.1016/S2666-7568
【tool:web_search】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://html.duckduckgo.com/html/?q=%2210.1016%2FS2666-7568%2823%2900258-1%22+mTOR+inhibitors+older+adults+phase+2b+phase+3+randomised+trials'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_search】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://html.duckduckgo.com/html/?q=%22Adjunctive+everolimus+therapy+for+treatment-resistant+focal-onset+seizures+associated+with+tuberous+sclerosis%22+trial+reference'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call run_python({"code":"import requests, re, json\n\ndoi='10.1016/S2666-7568(23)00258-1'\nmsg=requests.get(f'https://api.crossref.org/works/{doi}', timeout=30,\n headers={'User-Agent':'Mozilla/5.0'}).json()['message']\nrefs=msg['reference']\nkw = re.compile(r'rapamycin|sirolimus|everolimus|temsirolimus|rapalog|mTOR inhibitor|mammalian target of rapamycin', re.I)\ntrialish_markers = re.compile(r't)
【tool:run_python】
{"ok": true, "stdout": "TOTAL 14\nROLE_COUNTS Counter({'primary/interventional': 8, 'follow-up/extension': 3, 'unclear': 2, 'ancillary': 1})\nFAMILY_COUNTS Counter({'Older-adult rapamycin family': 2, 'Other/unknown family': 2, 'Geographic atrophy sirolimus family': 2, 'Rheumatoid arthritis mTOR family': 2, 'EXIST-3 family': 2, 'Temsirolimus QT family': 1, 'MSA sirolimus family': 1, 'Pulmonary hypertension everolimus family': 1, 'Breast cancer everolimus family': 1})\n25\tprimary/interventional\tOlder-adult rapamycin family\t10.1016/S2666-7568(21)00062-3\tTargeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials\n26\tunclear\tTemsirolimus QT family\t10.1007/s00280-012-1845-7\tA single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults\n33\tprimary/interventional\tOlder-adult rapamycin family\t10.1016/j.exger.2017.12.026\tA randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects\n34\tunclear\tOther/unknown family\t10.1016/j.ophtha.2011.07.034\tA randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema\n35\tancillary\tGeographic atrophy sirolimus family\t10.1016/j.oret.2017.08.015\tTreatment of geographic atrophy with intravitreal sirolimus:
→ call write_note({"tags":["4360dd15","lesson","evidence-retrieval","critical-review"],"text":"!! 本轮批判性结论：Crossref 引用链抽取出来的“人类临床候选”仍然过宽\n\n本轮不再继续找 mmc1.pdf 镜像，而是专门检验上一轮的抽取结果是否稳健。结果显示：\n\n- 用 DOI `10.1016/S2666-7568(23)00258-1` 的 Crossref `reference` 数组，按关键词 + trialish 标记过滤后，得到 **14 条**候选，而不是之前口径里的 13 条。\n- 这 14 条里有：\n - `primary/interventional`: 8\n - `follow-up/extension`: 3\n - `ancillary`: 1\n - `unclear`: 2)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\Iter-4360dd15-0049-crossref-candidate-overgeneration-critique.tid", "title": "Iter-4360dd15-0049-crossref-candidate-overgeneration-critique"}
【assistant】
本轮我没有再找镜像，而是专门“打假”上一轮的 Crossref 抽取规则。结果很明确：
- 规则一跑得到 **14 条**候选，而不是 13 条；
- 其中混入了 **follow-up / extension / ancillary**，说明当前规则**过宽**；
- 更关键的是，候选集合明显跨到了眼科、RA、癫痫/TSC、肺高压、肿瘤等适应证，**不能证明**它等于综述真正的“纳入临床研究集”。
所以这轮的结论不是“找到答案”，而是证伪了一个更强的说法：
**当前 Crossref 规则只能复现一个宽松的 mTOR/rapalog 人类临床引用集合，不能稳定复现综述的真实纳入项。**
我已经把这个批判结果写入记忆：`Iter-4360dd15-0049-crossref-candidate-overgeneration-critique`。
<NEXT_FOCUS>把过滤规则收紧为“仅原始临床研究，显式排除 extension/follow-up/ancillary”，并逐条核对那 14 条里到底哪一条是误纳入。</NEXT_FOCUS>